We headed to Newport Beach, California, for a State of the Science Summit on Gastrointestinal Cancers, which focused on the evolving paradigms of colorectal cancer, pancreatic cancer, neuroendocrine tumors, gastric cancer, and hepatocellular carcinoma.
We visited Summit, New Jersey for a State of the Science Summit on non–small cell lung cancer (NSCLC). The meeting covered the current standard of care for early-stage lung cancer, approaches to locoregionally advanced NSCLC, updates in EGFR-positive NSCLC, and more.
The 2018 ESMO Congress brought us all the way to Munich, Germany. At this annual congress, data across various tumor types were presented, including genitourinary malignancies, breast cancer, head and neck squamous cell carcinoma, melanoma, gastrointestinal malignancies, and lung cancer.
We traveled to Cleveland, Ohio for a State of the Science Summit on Hematologic Malignancies. The meeting covered the evolving paradigm of chronic lymphocytic leukemia, updates in mantle cell lymphoma, treatment options for patients with newly diagnosed and relapsed/refractory multiple myeloma, unmet needs in myeloproliferative neoplasms, interesting genomic research in acute myeloid leukemia, and the challenges with treating patients with myelodysplastic syndrome.
We returned to San Francisco, California for a State of the Science Summit on Breast Cancer. The meeting covered the use of CDK4/6 inhibitors in metastatic hormone receptor-positive breast cancer, adjuvant and neoadjuvant HER2-targeted therapy in early-stage HER2-positive disease, immunotherapy in triple-negative disease, and more.
We visited San Francisco, California for a State of the Science Summit on Hematologic Malignancies. The meeting covered novel agents and combinations in lymphoma, updates in acute and chronic leukemias, and modalities in the management of multiple myeloma.
We visited Chicago, Illinois for a State of the Science Summit on Renal Cell Carcinoma and Bladder Cancer. The meeting covered the genomics of bladder cancer, novel approaches to non-muscle invasive bladder cancer, side effect management from immunotherapy, as well as the integration of immunotherapy, chemotherapy, and targeted therapy in genitourinary cancers.
We traveled to Seattle, Washington for another State of the Science Summit on Hematologic Malignancies with faculty of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center. The meeting covered the latest updates in Hodgkin lymphoma, mantle cell lymphoma, multiple myeloma, and more.
We visited Dearborn, Michigan for a State of the Science Summit on Hematologic Malignancies with faculty of Karmanos Cancer Institute.
We headed to Tampa, Florida for a State of the Science Summit on Hematologic Malignancies. The meeting covered updates in follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic myeloid leukemia, acute myeloid leukemia, myeloproliferative neoplasms, and CAR T-cell therapy.